InxMed Limited Files for Hong Kong IPO with Near-Commercial FAK Inhibitor Ifebemtinib
InxMed Limited, a China-based late-stage clinical biotechnology company, has filed a prospectus for an initial...
InxMed
InxMed Secures HK$100 M Private Placement from TruMed Health
On August 26, 2025, Hong Kong‑listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has...
InxMed’s Ifebemtinib Earns Breakthrough Therapy Designation for NSCLC Treatment in China
China-based InxMed (Nanjing) Co., Ltd has announced that the Center for Drug Evaluation of the...
Shanghai Escugen Partners with InxMed for Global Development Rights to EZWi-Fit Platform
Shanghai Escugen has entered into a partnership with InxMed (Nanjing) Co., Ltd, granting the Chinese...
InxMed Presents Positive Data for FAK Inhibitor Ifebemtinib at ESMO 2023
China-based firm InxMed (Nanjing) Co., Ltd has updated two clinical studies for its first-in-class small-molecule...
InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs
China-based firm InxMed (Nanjing) Co., Ltd has announced a strategic partnership with compatriot firm GeneQuantum...
InxMed and Huaota Bio Partner to Develop Novel Solid Tumor Combination Therapy
China-based InxMed (Nanjing) Co., Ltd has entered into a strategic partnership with Shanghai Huaota Biopharmaceutical...
InxMed Receives $10M Debt Financing from SPD Silicon Valley Bank to Advance FAK Inhibitor IN10018
China-based biotech firm InxMed (Nanjing) Co., Ltd announced it has received $10 million in debt...